login
register
Home
Getting Started
ChartMill Overview
Growth Traders
Technical Swing Traders
Long Term Investors
Tools
Stock Screener
Stock Charts
Full Screen Stock Charts
Market Monitor
Sectors
Earnings
Analyzer
Insider Trading
Up- and Downgrades
Stock Market
Top Gainers and Losers
New 52 Week High and Low
Gap Up and Gap Down
Most Active
Premarket Movers
After-Hours Movers
Earnings Calendar
USA Market Overview
Canada Market Overview
Europe Market Overview
Trading Ideas
News
Blog
Documentation
Documentation Center
Videos
Indicators
Properties
Screener Market data
Popular Articles
Bull Flags
Relative Strength
Pocket Pivots
Support and Resistance
RSI Indicator
MACD Indicator
Piotroski F-score
Squeeze Plays
Weinstein
Technical Breakout Setups
Trading Tips
Premarket Movers
Gap Up Stocks
Best Dividend Stocks
Bullish Engulfing Pattern
Ascending Triangle Pattern
Swing Trading
All articles ...
Subscriptions
Swing Trading Course
Account
Disclaimer
Affiliate
Contact
Privacy
ITERUM THERAPEUTICS PLC (ITRM) Stock News
USA
- NASDAQ:ITRM -
IE000TTOOBX0
-
Common Stock
0.75
USD
+0.08 (+11.23%)
Last: 10/20/2025, 8:00:02 PM
0.7999
USD
+0.05 (+6.65%)
After Hours:
10/20/2025, 8:00:02 PM
Overview
Stock Chart
Technical Analysis
Fundamental Analysis
Analyst Ratings
Earnings Estimates
Financials
Ownership
News
ITRM Latest News, Press Relases and Analysis
All
Press Releases
7 days ago - By: Iterum Therapeutics PLC
Iterum Therapeutics to Present Data at IDWeek 2025
a month ago - By: Iterum Therapeutics PLC
Iterum Therapeutics Provides Business Update
2 months ago - By: Iterum Therapeutics PLC
Iterum Therapeutics launches ORLYNVAH™, the first and only oral penem antibiotic in the U.S.
3 months ago - By: The Motley Fool
ITRM Reports Results
3 months ago - By: Iterum Therapeutics PLC
Iterum Therapeutics Reports Second Quarter 2025 Financial Results
3 months ago - By: Benzinga
- Mentions:
AFG
CXDO
YUM
PACK
...
Earnings Scheduled For August 5, 2025
3 months ago - By: Benzinga
Insights Ahead: Iterum Therapeutics's Quarterly Earnings
a year ago - By: Iterum Therapeutics PLC
Iterum Therapeutics Regains Full Nasdaq Compliance
3 months ago - By: Iterum Therapeutics PLC
Iterum Therapeutics to Report Second Quarter 2025 Financial Results on August 5, 2025
4 months ago - By: Iterum Therapeutics PLC
Iterum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
4 months ago - By: Iterum Therapeutics PLC
Iterum Names Christine Coyne as Chief Commercial Officer to Lead ORLYNVAH™ Launch and Commercial Growth
4 months ago - By: Iterum Therapeutics PLC
Iterum Therapeutics Announces Publication of REASSURE Trial in NEJM Evidence
4 months ago - By: Iterum Therapeutics PLC
Iterum Therapeutics Announces Partnership for Commercialization Services
5 months ago - By: Iterum Therapeutics PLC
Iterum Therapeutics Announces Extension of Term of Promissory Note
5 months ago - By: Iterum Therapeutics PLC
Iterum Therapeutics Reports First Quarter 2025 Financial Results
6 months ago - By: Iterum Therapeutics PLC
Iterum Therapeutics Announces Closing of $5 Million Registered Direct Offering of Ordinary Shares
6 months ago - By: Iterum Therapeutics PLC
Iterum Therapeutics Announces $5 Million Registered Direct Offering of Ordinary Shares
6 months ago - By: Iterum Therapeutics PLC
Iterum Therapeutics Presented a Scientific Poster at ECCMID 2025 Highlighting the Impact of Age on Antibiotic Resistance and Efficacy of Antibiotics
9 months ago - By: Iterum Therapeutics PLC
Iterum Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results
9 months ago - By: Iterum Therapeutics PLC
Iterum Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results on February 7, 2025
a year ago - By: Iterum Therapeutics PLC
Iterum Therapeutics Reports Third Quarter 2024 Financial Results
a year ago - By: Iterum Therapeutics plc
Iterum Therapeutics to Host Morning Conference Call on U.S. FDA Approval of ORLYNVAH™ (Oral Sulopenem) for the Treatment of Uncomplicated Urinary Tract Infections
a year ago - By: Iterum Therapeutics PLC
Iterum Therapeutics Receives U.S. FDA Approval of ORLYNVAH™ (Oral Sulopenem) for the Treatment of Uncomplicated Urinary Tract Infections
a year ago - By: Iterum Therapeutics PLC
Iterum Therapeutics to Present Data at IDWeek 2024
a year ago - By: Iterum Therapeutics PLC
Iterum Therapeutics to Participate at the 2024 Maxim Healthcare Virtual Summit
Please enable JavaScript to continue using this application.